| Market Cap | 1.32B 1.18B 1.09B 989M 1.85B 125B 1.87B 13.05B 5.2B 65.6B 4.94B 4.83B 208B | P/E 2026 * |
-4.77x | P/E 2027 * | -3.67x |
|---|---|---|---|---|---|
| Enterprise Value | 708M 635M 587M 532M 994M 67.42B 1.01B 7.02B 2.8B 35.28B 2.66B 2.6B 112B | EV / Sales 2026 * |
16.9x | EV / Sales 2027 * | 16.9x |
| Free-Float |
99.62% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Nektar Therapeutics
| 1 day | -0.71% |
| Manager | Title | Age | Since |
|---|---|---|---|
Howard Robin
CEO | Chief Executive Officer | 73 | 01/01/2007 |
Linda Rubinstein
DFI | Director of Finance/CFO | 60 | 15/05/2026 |
| Chief Tech/Sci/R&D Officer | 52 | 01/07/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Roy Whitfield
BRD | Director/Board Member | 72 | 01/08/2000 |
Robert Chess
CHM | Chairman | 69 | 01/05/1992 |
Howard Robin
BRD | Director/Board Member | 73 | 01/02/2007 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.71% | +1.97% | - | - | 1.32B | |
| +0.34% | -3.03% | +37.45% | +61.06% | 64.14B | |
| +1.21% | +2.91% | +12.50% | +84.32% | 55.53B | |
| +1.35% | +1.72% | +12.98% | +105.14% | 53.03B | |
| -0.37% | -0.28% | +27.41% | +56.66% | 45.99B | |
| -0.16% | -2.07% | +18.90% | +100.61% | 42.45B | |
| +1.19% | +1.73% | +229.08% | +940.52% | 40.45B | |
| -0.26% | -4.20% | +10.86% | +45.18% | 32.25B | |
| -1.19% | +44.57% | +106.40% | +92.72% | 34.47B | |
| -2.72% | -8.79% | +22.58% | -5.63% | 24.23B | |
| Average | -0.13% | +3.82% | +53.13% | +164.51% | 43.62B | |
| Weighted average by Cap. | +0.18% | +3.13% | +50.13% | +162.05% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 41.82M 37.52M 34.69M 31.42M 58.7M 3.98B 59.41M 415M 165M 2.08B 157M 154M 6.62B | 53.42M 47.93M 44.31M 40.13M 74.97M 5.09B 75.88M 530M 211M 2.66B 200M 196M 8.45B |
| Net income | -246M -221M -204M -185M -346M -23.47B -350M -2.44B -973M -12.28B -925M -905M -38.99B | -363M -325M -301M -272M -509M -34.54B -515M -3.6B -1.43B -18.07B -1.36B -1.33B -57.37B |
| Net Debt | -608M -546M -505M -457M -854M -57.94B -864M -6.03B -2.4B -30.32B -2.28B -2.23B -96.25B | -415M -373M -344M -312M -583M -39.55B -590M -4.12B -1.64B -20.7B -1.56B -1.53B -65.7B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
